Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Consensus Rating of “Hold” by Brokerages

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned an average rating of “Hold” from the ten research firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $9.33.

A number of equities analysts recently commented on the company. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “neutral” rating and issued a $4.00 price objective on shares of Fulcrum Therapeutics in a research note on Thursday, November 14th.

Fulcrum Therapeutics Price Performance

Fulcrum Therapeutics stock opened at $3.96 on Monday. The stock’s 50 day moving average is $4.22 and its 200 day moving average is $5.24. The firm has a market cap of $213.60 million, a P/E ratio of -12.77 and a beta of 2.06. Fulcrum Therapeutics has a one year low of $2.86 and a one year high of $13.70.

Institutional Investors Weigh In On Fulcrum Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its holdings in shares of Fulcrum Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 12,002 shares of the company’s stock valued at $43,000 after acquiring an additional 4,701 shares in the last quarter. Walleye Capital LLC bought a new stake in shares of Fulcrum Therapeutics during the third quarter valued at approximately $59,000. Intech Investment Management LLC bought a new stake in shares of Fulcrum Therapeutics during the third quarter valued at approximately $62,000. Renaissance Technologies LLC bought a new stake in shares of Fulcrum Therapeutics during the second quarter valued at approximately $82,000. Finally, SG Americas Securities LLC increased its holdings in shares of Fulcrum Therapeutics by 26.5% during the third quarter. SG Americas Securities LLC now owns 33,019 shares of the company’s stock valued at $118,000 after acquiring an additional 6,926 shares in the last quarter. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.